-+ 0.00%
-+ 0.00%
-+ 0.00%

Tulane Ventures invests USD 250,000 in phage therapy startup Biophoundry

PUBT·10/02/2026 16:57:03
Tulane Ventures invests USD 250,000 in phage therapy startup Biophoundry
  • Tulane Ventures, part of Tulane University Innovation Institute, invested 250,000 in Biophoundry in a private financing round.
  • Biophoundry is a Tulane spinout developing engineered phage therapies targeting antibiotic-resistant bacterial infections.
  • Funding supports a provider-partnership pilot with a Gulf South regional hospital, preclinical work, preparation for an FDA IND filing.
  • Biophoundry’s Phax platform aims to engineer targeted therapeutic phages faster, using computational design, rapid engineering, cell-free synthesis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tulane University Innovation Institute published the original content used to generate this news brief on October 02, 2026, and is solely responsible for the information contained therein.